NIKKEI 225
38,787.38 -132.92 (-0.34%) HANG SENG
19,553.61 +177.11 (+0.91%) CRUDE OIL
80.02 -0.04 (-0.05%) GOLD FUTURES
2,426.70 +9.30 (+0.38%) DOW
40,003.59 +134.19 (+0.34%) Bitcoin GBP
52,233.19 -421.81 (-0.80%)
BAX Nov 2024 40.000 put
| Previous close | 4.40 |
| Open | 5.90 |
| Bid | 5.20 |
| Ask | 6.20 |
| Strike | 40.00 |
| Expiry date | 2024-11-15 |
| Day's range | 5.90 - 5.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 103 |
PR NewswireBAXTER ANNOUNCES MISSION AND LOGO FOR PROPOSED KIDNEY CARE COMPANY VANTIVE
Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive.
ZacksBaxter's (BAX) Clinolipid Gets FDA's Expanded Indication
Baxter's (BAX) receipt of the latest expanded indication for Clinolipid is expected to meet the diverse nutritional needs of patients, ranging from preterm neonates to adults.
Business WireBaxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
DEERFIELD, Ill., May 13, 2024--Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates. Clinolipid is Baxter’s proprietary mixed oil lipid emulsion that is used to provide calories and essential fatty acids in parenteral (intravenous) nutrition (PN) when oral or enteral nutrition is not possible, insuffici
